• 1
    Lee DS, Schull MJ, Alter DA, et al. Early deaths in patients with heart failure discharged from the emergency department: a population-based analysis. Circ Heart Fail. 2010; 3:22835.
  • 2
    Mueller C, Scholer A, Laule-Kilian K, et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med. 2004; 350:64754.
  • 3
    Maisel AS, Peacock WF, McMullin N, et al. Timing of immunoreactive B-type natriuretic peptide levels and treatment delay in acute decompensated heart failure: an ADHERE (Acute Decompensated Heart Failure National Registry) analysis. J Am Coll Cardiol. 2008; 52:53440.
  • 4
    Wuerz RC, Meador SA. Effects of prehospital medications on mortality and length of stay in congestive heart failure. Ann Emerg Med. 1992; 21:66974.
  • 5
    Peacock WF, Emerman C, Costanzo MR, Diercks DB, Lopatin M, Fonarow GC. Early vasoactive drugs improve heart failure outcomes. Congest Heart Fail. 2009; 15:25664.
  • 6
    Peacock WF IV, DeMarco T, Fonarow GC, et al.; ADHERE Investigators. Cardiac troponin and outcome in acute heart failure. NEJM. 2008; 358:211726.
  • 7
    Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J. 2008; 29:2388442.
  • 8
    Peacock WF, Fonarow GC. Preamble. Society of Chest Pain Centers Recommendations for the Evaluation and Management of the Observation Stay Acute Heart Failure Patient. Crit Pathways in Cardiol. 2008; 7:889.
  • 9
    Jougasaki M, Burnett JC Jr. Adrenomedullin: potential in physiology and pathophysiology. Life Sci. 2000; 66:85572.
  • 10
    Jougasaki M, Rodeheffer RJ, Redfield MM, et al. Cardiac secretion of adrenomedullin in human heart failure. J Clin Invest. 1996; 97:23706.
  • 11
    Jougasaki M, Wei CM, McKinley LJ, Burnett JC. Elevation of circulating and ventricular adrenomedullin in human congestive heart failure. Circulation. 1995; 92:2869.
  • 12
    Nishikimi T, Saito Y, Kitamura K, et al. Increased plasma levels of adrenomedullin in patients with heart failure. J Am Coll Cardiol. 1995; 26:142431.
  • 13
    Struck J, Tao C, Morgenthaler NG, Bergmann A. Identification of an Adrenomedullin precursor fragment in plasma of sepsis patients. Peptides. 2004; 25:136972.
  • 14
    Morgenthaler NG, Struck J, Alonso C, Bergmann A. Measurement of midregional proadrenomedullin in plasma with an immunoluminometric assay. Clin Chem. 2005; 51:18239.
  • 15
    Khan SQ, O’Brien RJ, Struck J, et al. Prognostic value of midregional pro-adrenomedullin in patients with acute myocardial infarction: the LAMP (Leicester Acute Myocardial Infarction Peptide) study. J Am Coll Cardiol. 2007; 49:152532.
  • 16
    Gegenhuber A, Struck J, Dieplinger B, et al. Comparative evaluation of B-type natriuretic peptide, mid-regional pro-A-type natriuretic peptide, mid-regional pro-adrenomedullin, and Copeptin to predict 1-year mortality in patients with acute destabilized heart failure. J Card Fail. 2007; 13:429.
  • 17
    Maisel A, Mueller C, Nowak R, et al. Mid-Region ProHormone Markers for Diagnosis and Prognosis in Acute Dyspnea: Results from the BACH (Biomarkers in ACute Heart failure) Trial. J Am Coll Cardiol. 2010; 55:206276.
  • 18
    Morgenthaler NG, Struck J, Alonso C, Bergmann A. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem. 2006; 52:1129.
  • 19
    Khan SQ, Dhillon OS, O’Brien RJ, et al. C-terminal provasopressin (Copeptin) as a novel and prognostic marker in acute myocardial infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) study. Circulation. 2007; 115:210310.
  • 20
    Stoiser B, Mortl D, Hulsmann M, et al. Copeptin, a fragment of the vasopressin precursor, as a novel predictor of outcome in heart failure. Eur J Clin Invest. 2006; 36:7718.
  • 21
    Heagerty PJ, Lumley T, Pepe MS. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics. 2000; 56:33744.
  • 22
    Fonarow GC, Adams KF Jr, Abraham WT, et al.; ADHERE Scientific Advisory Committee, Study Group, and Investigators. Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA. 2005; 293:57280.
  • 23
    O’Neill JO, Bott-Silverman CE, McRae AT, et al. B-type natriuretic peptide levels are not a surrogate marker for invasive hemodynamics during management of patients with severe heart failure. Am Heart J. 2005; 149:3639.